Inhaled Amikacin Versus Placebo in Patients With Ventilator-associated Tracheobronchitis

The primary objective of the AMIVAT trial is to assess whether a 5-day course of inhaled amikacin, compared to placebo, reduces the incidence of progression to ventilator-associated pneumonia (VAP) at day 28 in intensive care unit (ICU) patients with ventilator-associated tracheobronchitis (VAT). Transition from VAT to VAP will be defined as the occurrence of a first VAP episode due to the same pathogens than those responsible for VAT.

NCT Number	NCT07665788
Lead Sponsor	University Hospital, Tours Collaborators: Aerogen
Conditions	Ventilator-Associated Pneumonia, Ventilator-Associated Tracheobronchitis
Enrollment	250 participants
Start Date	2026-06-01
Primary Completion	2029-07-01 (estimated)
Study Completion	2029-09-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-24